MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Genetics comes to help in anticoagulant dosing

Back to research news Blogs list Cancer blog  


Subscribe To Research News RSS Feed  RSS content feed What is RSS feed?

Genetics comes to help in anticoagulant dosing




Each year in the United States, doctors start about 2 million patients on warfarin (Coumadin), an anticoagulant drug that's notoriously hard to administer. Now a study from the International Warfarin Pharmacogenetics Consortium (IWPC), which includes scientists from Washington University School of Medicine in St. Louis, confirms that using a patient's genetic information can make it easier to get the warfarin dose right.



Genetics comes to help in anticoagulant dosing

"If the warfarin dose is too high, patients are at risk of hemorrhage, and if it's too low, they risk blood clots that can lead to stroke, heart attack or even death," says Brian F. Gage, M.D., associate professor of medicine at the School of Medicine and director of the outpatient Anticoagulation Service at Barnes-Jewish Hospital. "Unfortunately, getting the warfarin dose right is like walking a tightrope it's very easy to give too little or too much".

Doctors prescribe warfarin to prevent blood clots or reduce the risk of stroke in patients with atrial fibrillation or artificial heart valves and those with a history of blood clots in the legs or lungs. It is also helpful in preventing blood clot formation after certain orthopedic surgeries such as knee or hip replacement.

Recently, Gage, Charles Eby, M.D., associate professor of pathology and immunology, and his colleagues at the School of Medicine developed improved dosing formulas. They calculate the warfarin dose by taking into account the effect of two genes involved in warfarin sensitivity and metabolism. Their research demonstrated that gene-based dosing could more quickly and accurately estimate the appropriate dose of warfarin.

The current study, reported in the Feb. 19, 2009, issue of the New England Journal (NEJM), gave gene-based dosing a rigorous test in an international collaboration that included more than 5,000 patients. The patients had been prescribed warfarin in the past and had achieved a stable effective dose.

For the study, the scientists calculated a warfarin dose for each of these patients with the gene-based dosing algorithm and with a formula based only on clinical data. Both formulas incorporate data such as age, body size, medications and race to estimate appropriate warfarin dose, but only the gene-based formula includes genetic information.

Using both formulas, the IWPC scientists checked how closely the calculated dose matched the dose actually used for each patient. In 60 percent of the patients, the gene-based formula got closer to the actual dose than did the clinical formula.

Almost half of the patients studied had either low or high warfarin dose requirements. Patients in these categories would be at high risk if given the wrong dose. The scientists showed that the gene-based formula was better than the clinical formula at identifying the patients at the low and high ends of the dosing spectrum. It provided significantly fewer overestimations in the low-dose group and significantly fewer underestimations in the high-dose group.

"This research study has made an important advance toward personalizing medicineit uses data from countries around the world to develop a gene-based strategy for warfarin dosing that could benefit a wide range of patients," said Jeremy M. Berg, Ph.D., director of the National Institute of General Medical Sciences, which partially funded the study. "This is a wonderful example of international cooperation and the results are particularly valuable for the United States, since our population is so genetically diverse".

The research lays important groundwork for a new clinical trial, the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. The trial, sponsored by the National Heart, Lung, and Blood Institute, one of the National Institutes of Health, will compare gene-based warfarin dosing to the traditional dosing approach in a prospective, randomized trial. Scheduled to open at the end of March, the trial will enroll 1,200 participants of diverse backgrounds and ethnicities at 12 clinical sites in the United States including Washington University School of Medicine. Eby will lead the COAG Central Genotyping Lab located at the School of Medicine. To enroll a patient beginning warfarin in this trial, doctors can contact Gage.


Posted by: Scott    Source




Did you know?
Each year in the United States, doctors start about 2 million patients on warfarin (Coumadin), an anticoagulant drug that's notoriously hard to administer. Now a study from the International Warfarin Pharmacogenetics Consortium (IWPC), which includes scientists from Washington University School of Medicine in St. Louis, confirms that using a patient's genetic information can make it easier to get the warfarin dose right.

Medicineworld.org: Genetics comes to help in anticoagulant dosing

Acute bacterial meningitis| Alzheimer's disease| Carpal tunnel syndrome| Cerebral aneurysms| Cerebral palsy| Chronic fatigue syndrome| Cluster headache| Dementia| Epilepsy seizure disorders| Febrile seizures| Guillain barre syndrome| Head injury| Hydrocephalus| Neurology| Insomnia| Low backache| Mental retardation| Migraine headaches| Multiple sclerosis| Myasthenia gravis| Neurological manifestations of aids| Parkinsonism parkinson's disease| Personality disorders| Sleep disorders insomnia| Syncope| Trigeminal neuralgia| Vertigo|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.